Exenatide (Byetta / Bydureon)

Exenatide was the original approved GLP-1 receptor agonist — first synthesized from a compound found in Gila monster venom, approved in 2005, a full decade before semaglutide reached the market. Real, large Phase 3 trials backed the approval, and it helped create the entire drug class this site covers elsewhere. Both branded products were discontinued by AstraZeneca in October 2024, superseded by newer, more effective GLP-1 drugs — it's a historical anchor now, not a currently available medicine.

What it is, and its real approval

Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum), which shares structural similarity with human GLP-1. Developed by Amylin Pharmaceuticals with Eli Lilly, it was FDA-approved as Byetta (twice-daily injection) on 28 April 2005 for type 2 diabetes as an add-on to metformin and/or a sulfonylurea — the first GLP-1 receptor agonist ever approved, a full decade before semaglutide. A once-weekly extended-release version, Bydureon, followed later.

The pivotal trial evidence

Approval rested on three 30-week, placebo-controlled Phase 3 trials in over 1,400 patients: Buse et al. (Diabetes Care 2004;27(11):2628-2635, PMID 15504997, sulfonylurea-treated patients), DeFronzo et al. (Diabetes Care 2005;28(5):1092-1100, PMID 15855572, metformin-treated patients), and Kendall et al. (Diabetes Care 2005;28(5):1083-1091, PMID 15855571, metformin-plus-sulfonylurea patients). All three found dose-dependent HbA1c reductions and weight loss versus placebo — real, controlled, foundational trials for the entire GLP-1 drug class.

Real safety warnings

Bydureon carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent carcinogenicity findings — the same warning class carried by liraglutide and semaglutide. All exenatide products carry warnings for acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases; the label states exenatide should not be restarted if pancreatitis is confirmed.

Discontinued in 2024

Exenatide's weight-loss and A1c effects were real but modest compared to the GLP-1 drugs that followed it — liraglutide, then semaglutide and tirzepatide, each showing progressively larger effect sizes. Its historical role is genuine: it proved the GLP-1 mechanism worked in humans and created the regulatory and clinical pathway every later entrant followed. That it's no longer sold is a real, current fact worth knowing if you're comparing it to this site's other GLP-1 pages.